A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

BackgroundLecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer’s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence. This study aims to analyze and compare adverse drug r...

Full description

Saved in:
Bibliographic Details
Main Authors: Haoxiang Hu, Yunhan Zhao, Jiesheng Mao, Jianghai He, Yihan Zhang, Hongyu Ye, Xiaokai Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Pharmacology
Subjects:
lecanemab
aducanumab
alzheimer’s disease (AD)
VigiAccess
FAERS
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1561020/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items